Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.

[1]  H. Yavuz,et al.  Toxic epidermal necrolysis treated with N‐acetylcysteine , 2014, Pediatrics international : official journal of the Japan Pediatric Society.

[2]  L. French,et al.  TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[3]  R. Marsden,et al.  Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus , 2012, Clinical and experimental dermatology.

[4]  P. Delvenne,et al.  Drug interactions with normal and TEN epidermal keratinocytes. , 2012, Current drug safety.

[5]  G. Piérard,et al.  Deciphering supportive treatment strategies for toxic epidermal necrolysis. , 2012, Current drug safety.

[6]  P. Humbert,et al.  Toxic epidermal necrolysis. , 2012, Current drug safety.

[7]  L. Naldi,et al.  Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study , 2011, Journal of burn care & research : official publication of the American Burn Association.

[8]  J. Wohlrab,et al.  Etoricoxib‐induced toxic epidermal necrolysis: Successful treatment with infliximab , 2010, The Journal of dermatology.

[9]  G. Piérard,et al.  Facing up to toxic epidermal necrolysis , 2010, Expert opinion on pharmacotherapy.

[10]  G. Piérard,et al.  The therapeutic potential of TNF-α antagonists for skin psoriasis comorbidities , 2010, Expert opinion on biological therapy.

[11]  A. Dunant,et al.  ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.

[12]  G. Piérard,et al.  New Insights in Toxic Epidermal Necrolysis (Lyell’s Syndrome) , 2010, Drug safety.

[13]  K. Delman,et al.  Commentary on pharmacotherapy of regional melanoma therapy , 2010, Expert opinion on pharmacotherapy.

[14]  A. Grzybowski.  Robert Willan – a versatile physician and scholar , 2009, International journal of dermatology.

[15]  A. Sadighha.  Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: definition of a new model based on translational research , 2009, International journal of dermatology.

[16]  E. Gubinelli,et al.  Toxic epidermal necrolysis successfully treated with etanercept , 2009, The Journal of dermatology.

[17]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[18]  A. Kołtan,et al.  Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. , 2008, Acta dermato-venereologica.

[19]  G. Famularo,et al.  Etanercept for Toxic Epidermal Necrolysis , 2007, The Annals of pharmacotherapy.

[20]  P. Helmbold,et al.  Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor‐α antibody infliximab: report of three cases , 2007 .

[21]  G. Piérard,et al.  Glutathione-S-Transferase Pi Expression in Toxic Epidermal Necrolysis: A Marker of Putative Oxidative Stress in Keratinocytes , 2006, Skin Pharmacology and Physiology.

[22]  N. Yawalkar,et al.  Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment , 2005 .

[23]  K. thestrup-pedersen,et al.  Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. , 2005, Acta dermato-venereologica.

[24]  C. Bunker,et al.  TREATMENT OF TOXIC EPIDERMAL NECROLYSIS WITH INTRAVENOUS IMMUNOGLOBULIN , 2003, International journal of clinical practice.

[25]  J. Wohlrab,et al.  Antitumour necrosis factor‐α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis , 2002, The British journal of dermatology.

[26]  A. Vanderkelen,et al.  Immunoregulatory Effector Cells in Drug-Induced Toxic Epidermal Necrolysis , 2000, The American Journal of dermatopathology.

[27]  G. Piérard,et al.  Epidermal calprotectin in drug‐induced toxic epidermal necrolysis , 1999, Journal of cutaneous pathology.

[28]  P. Redondo,et al.  Drug‐induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N‐acetylcysteine , 1997, The British journal of dermatology.

[29]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.